VolitionRxVNRX
Recorded

VolitionRx 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration49 minParticipants8

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hello, everyone, and thank you for standing by. Welcome to VolitionRx Limited's third quarter 2026 earnings conference call. During today's presentation, all parties will be in a listen-only mode. Following the presentation, the conference will be be open for questions. If you have a question, please press the star key followed by the number 1 on your touchtone phone. If you would like to withdraw your question, please press the star key followed by the number 2. If you're using speaker equipment, please lift the handset before making your selections. This conference is being recorded today, November 13th, 2026. I would now like to turn the conference over to Rodney Rootsaert, Corporate Secretary.

Rodney RootsaertCorporate Secretary

Please go ahead. Thank you, and welcome, everyone, to today's earnings conference call for VolitionRx Limited.

Rodney RootsaertCorporate Secretary

Before we begin, I'd like to remind everyone that some of the information discussed on this conference call will include forward-looking statements covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on our beliefs as well as assumptions we have used based on information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties, and assumptions. Actual future results may vary significantly based on a number of factors that may cause the actual results or events to be materially different from future results, performance, or achievements expressed or implied by these statements.

Rodney RootsaertCorporate Secretary

We have identified various risk factors associated with our operations in our most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and other filings with the Securities and Exchange Commission. We do not undertake an obligation to update any of these forward-looking statements made during the course of this call. Cameron Reynolds, Group Chief Executive Officer, will open the call, providing a summary of recent key achievements, and will then hand over to Terig Hughes, Group Chief Financial Officer, to give a financial report before returning back to Cameron, who will discuss upcoming milestones. We will then open the conference call to a question-and-answer session. And with that, I'll turn the call over to Cameron.

Cameron ReynoldsGroup CEO

Thanks, Rodney, and thank you, everyone, for joining Volition's earnings call today. As always, we very much appreciate your time given the busy earnings season. I'll begin just by saying I have a croaky throat today, so I will take it nice and slow, and I apologize for my voice. It has been a very full past quarter as we have continued to execute our plan to commercialize our game-changing Nu.Q platform. This has involved work on a wide range of commercialization efforts focused on licensing our products and technology worldwide. At the same time, we have taken decisive action to strengthen our financial profile by both cutting costs and significantly reducing debt, which our CFO, Terry, will outline later. We have made strong progress across our key product pillars this year, evidencing clinical utility in a very wide range of uses and driving commercialization.

Cameron ReynoldsGroup CEO

Taking each in turn, starting with Nu.Q NETs. At the start of the last quarter, we issued a comprehensive update video and PDF showcasing the significant scientific and clinical evidence we have amassed relating to our Nu.Q NETs products and listing the extensive base of data now published. Results consistently showed that our Nu.Q NETs H3.1 assay accurately distinguishes sepsis from non-infectious systemic inflammation, is highly correlated with disease severity, and provides excellent prognostic utility for outcomes such as organ failure and mortality. Professor Gilly Adam, one of the world's leading experts in sepsis, believes Nu.Q NETs could be a game-changer in modifying a patient's trajectory and that introducing Nu.Q NETs into hospitals could lead to new ways of treating sepsis, improving patient survival, and the quality of life of survivors. He believes NETs themselves will become a separate treatable trait.

Cameron ReynoldsGroup CEO

This is a very powerful testament from a top KOL who strongly believes our test will be commonly used in routine use. Routine use will be the key. We are well progressed in getting our test used in routine use in Europe and hope to have an update in the current quarter. Having clinicians routinely using our test in sepsis will be a defining moment for Volition in our long journey. Excitingly for Nu.Q NETs, we have also made incredible progress in the development and evaluation of our lateral flow prototype assay. The journey to our lateral flow test started a little over one year ago in July 2025, when we announced the quantification of nucleosomes in whole venous blood using our lateral flow prototype assay. In April of this year, we reported the technical breakthrough of being able to detect nucleosomes in capillary blood or finger prick blood.

Cameron ReynoldsGroup CEO

We announced that we have demonstrated correlation of the lateral flow prototype assay and our established CE-marked automated Nu.Q NETs assay in samples of critically ill confirmed sepsis patients in the intensive care unit. The ability to rapidly identify high-risk patients at the point of care by quantifying their nucleosome levels using a finger prick sample and simple lateral flow device aims to enable quicker clinical decision-making and consequently better patient outcomes. This prototype technology has the exciting potential to strengthen our product portfolio. With recent estimates indicating approximately 166 million cases of sepsis worldwide, the addressable market is huge. All-cause sepsis-related deaths in 2021 represented 31.5% of total global deaths, with the highest burden of mortality in lower-middle-income countries.

Cameron ReynoldsGroup CEO

This lateral flow test is a potential game-changer, not only in diseases where time is critical, such as sepsis, but also in significantly expanding potential use cases beyond traditional hospital infrastructure. It also creates a compelling pathway into underserved lower-middle-income countries where lab infrastructure may be weak or nonexistent. Last month, we announced another very important step with the LOI with Missionpharma. Missionpharma, based in Denmark and part of the Toyota Tsusho Group, is a leading global supplier of healthcare products and innovative solutions, impacting the lives of over 100 million patients annually. By expanding beyond centralized lab testing, this finger prick sample test could be used worldwide, beyond solely high-income countries. With the help of Missionpharma, we aim to accelerate commercialization and market access, particularly in resource-constrained countries and humanitarian emergency settings.

Cameron ReynoldsGroup CEO

Missionpharma has strong partnerships with a broad institutional base, including with United Nations, the UN, agencies specialized in global health and humanitarian response. Following on from discussions with key global health institutions, it is clear that Volition's clinical intended use should initially focus on one well-defined use to start. That is developing and validating a tool for triaging and prognostication for neonatal sepsis, that is sepsis in newborns and young infants. Missionpharma has seen a very strong interest from partners in this intended use and customers in Volition's innovative diagnostic solutions, particularly in low and middle-income countries and humanitarian emergency settings. They are looking forward to collaborating with Volition, with the aim of saving millions of children's lives annually.

Cameron ReynoldsGroup CEO

They also believe Nu.Q NETs lateral flow test prototype is a potential game-changer, and they are delighted that Volition and Missionpharma have now established a basis for collaboration, with initial focus on evaluating the lateral flow prototype with a well-defined and impactful clinical utility, as above, sepsis in newborns and young infants. Outside of sepsis, but still with Nu.Q NETs and diseases associated with Nu.Q NETs, we are working with Sysmex Corporation, a multi-billion dollar company listed on the Tokyo Stock Exchange. Sysmex is a global leader in the field of in vitro diagnostics for hemostasis and thrombosis, among other diseases, where neutrophil extracellular traps, NETs, play such an important role. We have already successfully transferred our Nu.Q NETs assay onto Sysmex's platform and are delighted they have commenced the optimization phase in diseases associated with NETosis.

Cameron ReynoldsGroup CEO

We aim to go to the next step and beginning commercialization phase with them in Q1 of next year. The collaboration is in addition to that announced last year with Werfen's Immunoassay Technology Center, a worldwide leader in specialized diagnostics. That agreement concerned another NETs-related disease, antiphospholipid syndrome, APS, and they too are making good progress. We believe that Volition's Nu.Q NETs test could provide not only improved diagnostic information to aid clinical decision-making and personalized care, but could also be a low-cost test to continue to monitor a patient's condition in many NETs-related diseases. Next up, Nu.Q Cancer, specifically Nu.Q Lung Cancer. Lung cancer is the major cause of cancer-related mortality worldwide. Nu.Q Cancer represents a significant advancement in lung cancer patient management, offering clinicians an additional tool to enhance precision in treatment, collection, and monitoring.

Cameron ReynoldsGroup CEO

We have made strong progress towards our initial French reimbursement submission for Nu.Q Lung Cancer, supported by our long-term collaborators at the Hospices Civils de Lyon, one of Europe's leading cancer centers. French reimbursement approval is the next step on the path to the first use of Nu.Q in clinical practice, an exciting prospect which is core to Volition's mission, using our tests to help save lives and improve outcomes. French reimbursement approval will be a major milestone for Volition in the commercialization and licensing of Nu.Q in the human cancer field, and once achieved, we anticipate introduction into routine clinical use in France, and will then set our sights on rolling out to other countries. Staying with cancer, but moving on to Nu.Q Capture-Seq technology. Our clinical paper detailing this technology has been peer-reviewed and published.

Cameron ReynoldsGroup CEO

Volition is, we believe, the first liquid biopsy company to focus on circulating cell-free nucleoproteins, and we have filed a number of new patents to protect this technology. Our goal is to secure a wide range of licensing agreements in the human diagnostic space, mirroring our strategy in the vet market, and we anticipate diverse deal structures with potential for upfront and milestone payments and future recurring revenue. We are in active discussions with several large liquid biopsy and diagnostic companies to accelerate the development of our Nu.Q Capture-Seq technology. We believe the potential use cases for Nu.Q Capture-Seq represent a significant commercial opportunity, with a total addressable market on an annualized basis of approximately $23 billion for the human multi-cancer early detection, MCED, use, and over $13 billion for minimal residual disease use, MRD.

Cameron ReynoldsGroup CEO

From a Nu.Q Vet perspective, we made solid progress with our research into the use of Nu.Q in cats, most notably our submission for peer review of our clinical manuscript in May. This paper reports the high accuracy of our Nu.Q Vet feline prototype assay in detecting lymphoma in cats, the most common cancer in the species. at 97% specificity, the assay detected 86% of feline lymphomas. This breakthrough marks the development of what we expect to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer, a significant unmet need in vet medicine. This opens up the potential for cancer screening and monitoring in cats. There are more than 60 million pet cats in the U.S. alone, 25% of which are senior cats, and therefore suitable for an annual check. This represents a tremendous commercial opportunity for Volition.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day